Brainomix raises €16.1M Series C round
18 March 2025· Oxford, United Kingdom· health, medical_imaging, ai, b2b, b2g, pure_software
To enable commercial expansion into the US and advance its portfolio of AI-powered technology into new therapeutic areas such as lung fibrosis
“Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
Investors
LeadParkwalk Advisors
Also participating
HostplusBoehringer Ingelheim Venture FundLifeSci Capital
About Brainomix
Headquarters
Oxford, United Kingdom
Founded
2010
Team Size
51–200
Sectors
healthmedical_imagingaib2bb2gpure_software